DICE Therapeutics Inc - Company Profile
Powered by
All the data and insights you need on DICE Therapeutics Inc in one report.
- Save hours of research time and resources with
our up-to-date DICE Therapeutics Inc Strategy Report
- Understand DICE Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Dice Therapeutics Inc (DICE Therapeutics), a subsidiary of Eli Lilly and Co is a biopharmaceutical company that focuses on the creation and development of immunological treatments for chronic diseases. Parent synergy and its proprietary platform technology, DELSCAPE, are its strengths, even as private ownership is a cause for concern. The company could benefit from the strong product pipeline, market potential: Crohn’s Disease and the growing market for cancer treatments. However, stringent regulations, technological changes, and reliance on third-party manufacturers could affect the company's growth.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer